Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Mucopolysaccharidosis Treatment Market Revenue Outlook: What CAGR Is Expected Through 2030?
The market for mucopolysaccharidosis treatments witnessed significant expansion historically and is projected to continue its upward trajectory, expanding from $2.58 billion in 2025 to $2.78 billion in 2026, reflecting a compound annual growth rate of 7.7%. Factors contributing to this growth in past years included a lack of widespread understanding of MPS disorders, the considerable expense associated with treatments, a gradual uptake of enzyme replacement therapies, limited opportunities for clinical research, and a dependence on global pharmaceutical supply chains.
The global market for mucopolysaccharidosis treatments is poised for substantial expansion over the coming years, projecting a rise to $3.79 billion by 2030, driven by a compound annual growth rate of 8.0%. This anticipated growth trajectory during the forecast period is fueled by several key factors, including intensified research in gene therapy, escalated healthcare expenditures, enhanced initiatives for screening rare diseases, extended insurance coverage, and the proliferation of personalized medicine platforms. Furthermore, the upcoming years are expected to witness significant market developments such as innovations in enzyme replacement therapy, a greater acceptance of stem cell transplantation, the continuous advancement of gene therapy methodologies, a heightened emphasis on early detection and newborn screening, and the establishment of more specialized treatment facilities.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11942&type=smp
Mucopolysaccharidosis Treatment Market Growth Momentum: Which Factors Are Influencing Demand?
The expanding occurrence of diverse mucopolysaccharidosis types is anticipated to significantly boost the future expansion of the mucopolysaccharidosis treatment market. Mucopolysaccharide, a type of intricate carbohydrate, accumulates within bodily tissues due to a deficiency in the essential enzyme needed for its breakdown. Therapies for mucopolysaccharidosis (MPS) can mitigate disease progression by curtailing glycosaminoglycan (GAG) production within the body, managing presenting symptoms, and preempting complications through a range of treatment modalities. For example, data from the Orphanet Journal of Rare Diseases, a French peer-reviewed open-access medical publication, indicated in July 2024 that the incidence rate for mucopolysaccharidosis IVa (MPS IVa) is approximately 1 per 201,000 live births, although this statistic is believed to fluctuate substantially across different demographic groups. Complementarily, the estimated birth prevalence for Mucopolysaccharidosis VI (MPS VI) falls within the range of 1 in 43,261 to 1 in 1,505,160, contingent upon the specific population studied. Consequently, the heightened incidence of various mucopolysaccharidosis forms is poised to be a primary driver for the mucopolysaccharidosis treatment market.
Mucopolysaccharidosis Treatment Market Segmentation: How Is The Market Structured Across Key Categories?
The mucopolysaccharidosis treatment market covered in this report is segmented –
1) By Treatment: Enzyme Replacement Therapy, Stem Cell Therapy
2) By Disease: Mucopolysaccharidosis- I, Mucopolysaccharidosis- II, Mucopolysaccharidosis-IV, Mucopolysaccharidosis-VI, Other Diseases
3) By Route Of Administration: Intravenous, Intracerebroventricular
4) By End-User: Hospitals, Specialty Clinics, Other End-Users
Subsegments:
1) By Enzyme Replacement Therapy: Idursulfase (Elaprase), Laronidase (Aldurazyme), Velaglucerase Alfa (Vpriv), Galsulfase (Naglazyme)
2) By Stem Cell Therapy: Hematopoietic Stem Cell Transplantation (HSCT), Umbilical Cord Blood Transplantation, Gene Therapy Approaches
Mucopolysaccharidosis Treatment Market Trends Reshaping Industry Growth
Leading entities within the MPS II therapeutic landscape are directing their efforts toward pioneering novel treatments, including AAV gene therapies, with the objective of correcting the fundamental genetic causes of the condition and achieving lasting neurological improvement. This advanced form of gene therapy is characterized by its precise genetic modification approach, employing adeno-associated viral vectors to introduce functional genes into brain cells, thereby facilitating sustained production of essential proteins that are either absent or insufficient. Demonstrating this commitment, REGENXBIO Inc., a biotechnology firm based in the United States, announced in August 2025 that the U.S. Food and Drug Administration had prolonged its evaluation period for RGX-121. This review extension was prompted by the incorporation of extended clinical data from all trial participants, which corroborated initial findings related to biomarkers and neurodevelopmental progress. The successful completion of pre-licensure inspections and the lack of identified safety issues suggest continued regulatory advancement, bolstering the prospect of this therapy becoming the inaugural single-administration treatment aimed at addressing the neurological symptoms of MPS II.
Mucopolysaccharidosis Treatment Market Competitive Landscape And Leading Companies
Major companies operating in the mucopolysaccharidosis treatment market are BioMarin Pharmaceuticals Inc., Sanofi S.A., Takeda Pharmaceutical Co. Ltd., JCR Pharmaceuticals Co. Ltd., Ultragenyx Pharmaceutical Inc., RegenxBio Inc., Sangamo Therapeutics Inc., Audentes Therapeutics Inc., Abeona Therapeutics Inc., Immusoft Corporation, Neurogene Inc., Mallinckrodt Pharmaceuticals, Green Cross Corporation, Denali Therapeutics Inc., Passage Bio Inc., Homology Medicines Inc., AVROBIO Inc., Rocket Pharmaceuticals Inc., Taysha Gene Therapies Inc., Freeline Therapeutics Holdings plc, 4D Molecular Therapeutics Inc., Sio Gene Therapies Inc., SpliceBio S.L., LogicBio Therapeutics Inc., Orchard Therapeutics plc, Asklepios BioPharmaceutical Inc.
Access The Complete Mucopolysaccharidosis Treatment Market Report:
Mucopolysaccharidosis Treatment Market Regional Analysis And Leading Geography
North America was the largest region in the mucopolysaccharidosis treatment market in 2025. The regions covered in the mucopolysaccharidosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
